Trilaciclib for prophylaxis of chemotherapy-induced myelosuppression in solid tumor patients: a systematic review and
Ting Yang1, Pengjie Yang2, Danyang Meng3
1College of Pharmacy, Inner Mongolia Medical University, Hohhot, China.
Objective:
To systematically evaluate the clinical benefit and safety of trilaciclib in solid-tumor patients receiving chemotherapy and to inform clinical practice.
Methods:
Following PRISMA guidelines and registered at PROSPERO (CRD420251053232), we searched PubMed, Embase and two other databases from inception to June 2025. Six randomized controlled trials enrolling 726 patients were included. Meta-analyses were performed with Review Manager 5.4.
Results:
Trilaciclib significantly reduced the incidence of severe neutropenia (SN) and febrile neutropenia (FN), shortened SN duration, and decreased the need for erythropoiesis-stimulating agents (ESAs), granulocyte colony-stimulating factor (G-CSF) and red-blood-cell (RBC) transfusions while lowering anemia rates. These benefits were not accompanied by increased risks of nausea, vomiting or fatigue. Progression-free survival (PFS) was significantly prolonged, whereas overall survival (OS) remained unchanged; patients aged ≥65 years and those enrolled in U.S. trials derived the greatest benefit. Limitations include the small number of RCTs, heterogeneous chemotherapy regimens, potential publication bias and short follow-up in some studies.
Conclusion:
Trilaciclib effectively prevents chemotherapy-induced myelosuppression in solid-tumor patients and can guide clinical use, but further well-designed studies are warranted to consolidate its efficacy and safety profile.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251053232URL.
Related Concept Videos
Drugs that Stabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules


